News

Insights from a genome-wide association study identify novel genetic loci

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to severe DED.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Neda Shamie, MD, previews the May 4 conference, where a faculty of ophthalmologists and optometrists will explore the latest advancements and controversies.

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

Celebrating a half-century of progress with Ophthalmology Times.

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.

Updated guidelines characterize IOLs by functional performance over optical design.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Phase I/II safety and efficacy study currently enrolling.

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.